Alkermes plc. Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
Alkermes plc. (ALKS) reported Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability of $26.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 · last filed 2026-07-28
- Alkermes plc. business combination, contingent consideration arrangements, change in amount of contingent consideration, liability for the quarter ending 2026-06-30 was $26.41M.
- Alkermes plc. business combination, contingent consideration arrangements, change in amount of contingent consideration, liability for the quarter ending 2025-06-30 was $0.00.
| Period end | Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability 3 month | Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability 6 month |
|---|---|---|
| 2026-06-30 | $26.41M 10-Q · filed 2026-07-28 | $26.41M 10-Q · filed 2026-07-28 |
| 2025-06-30 | $0.00 10-Q · filed 2026-07-28 | $0.00 10-Q · filed 2026-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |